Introduction
============

MicroRNA are noncoding small RNA that bind target sites either in the 3′ untranslated region (UTR) of mRNA to inhibit translation or at the coding regions to degrade the messages ([@b16-grsb-2007-263]; [@b27-grsb-2007-263]; [@b1-grsb-2007-263]; [@b17-grsb-2007-263]). Mature microRNAs (miRNA) are approximately 22 nucleotides in length and are expressed under the control of an RNA polymerase II promoter. The catalogue of human miRNA has expanded substantially in the last few years and the number of miRNA species is predicted to be close to one thousand ([@b9-grsb-2007-263]). Loss-of-function mutations have greatly facilitated elucidation of the biological functions of miRNA ([@b1-grsb-2007-263]) including their roles in development, cell differentiation ([@b1-grsb-2007-263]; [@b23-grsb-2007-263]), lifespan ([@b5-grsb-2007-263]) and in diseases such as cancer ([@b9-grsb-2007-263]) and neurodegeneration ([@b3-grsb-2007-263]). In mammals, neural tissues are believed to manifest the most complex and specific miRNA expression patterns relative to other organs ([@b2-grsb-2007-263]; [@b32-grsb-2007-263]).

Alzheimer disease (AD) is a dementing illness characterized by progressive neuronal degeneration, gliosis, and the accumulation of intracellular inclusions (neurofibrillary tangles) and extracellular deposits of amyloid (senile plaques) in discrete regions of the basal forebrain, hippocampus, and association cortices ([@b6-grsb-2007-263]; [@b29-grsb-2007-263]). The etiology of sporadic AD is likely multifactorial, with carriage of the apolipoprotein E ɛ4 (APOE4) allele constituting a strong risk factor for the development of this condition ([@b12-grsb-2007-263]).

Gene expression studies in AD have shown substantial downregulation of various mRNA species in brain ([@b25-grsb-2007-263]), peripheral blood mononuclear cells (BMC) ([@b20-grsb-2007-263]) and lymphocytes ([@b28-grsb-2007-263]) relative to non-demented control values. Furthermore, numerous investigations have implicated impairment of protein synthesis in AD tissues ([@b13-grsb-2007-263]) and diminished concentrations of specific proteins in the cerebrospinal fluid (CSF) of these patients ([@b26-grsb-2007-263]). In a small study of 13 miRNAs, levels of miR-9, miR-125b, and miR-128 were found to be increased in human AD hippocampus relative to control values ([@b19-grsb-2007-263]). In light of the above, we hypothesized that augmented miRNA expression may be responsible for the suppression of specific mRNA species both in AD brain and peripheral tissues. To test this hypothesis in the latter, we screened 462 human miRNA (from let-7 family to miR-663) in BMC derived from well-characterized cases of mild sporadic AD and age-matched normal elderly control subjects and, based on predicted miRNA targets, ascertained whether the accruing data may account for the patterns of mRNA downregulation in Alzheimer BMC previously reported by our laboratories ([@b20-grsb-2007-263]).

Materials and Methods
=====================

Subjects
--------

This study was approved by the Research Ethics Committee of the Sir Mortimer B. Davis Jewish General Hospital (JGH). Written informed consent was obtained from all patients or their primary caregivers. Recruited patients with sporadic AD were assessed by a neurologist or geriatrician at the JGH-McGill University Memory Clinic, a tertiary care facility for the evaluation of memory loss in Montreal. All AD subjects underwent formal neuropsychological testing as previously described ([@b6-grsb-2007-263]; [@b22-grsb-2007-263]). Normal elderly controls (NEC) were recruited from Family Practice Clinics at the JGH. The latter scored within one SD of age- and education-standardized normal values on a series of memory and attention tests. The Mini-Mental State Examination (MMSE) ([@b8-grsb-2007-263]) was administered to all subjects. Subjects with chronic metabolic and inflammatory conditions or acute illness were excluded from the study. Student's unpaired t-test was performed to assess statistical differences in age, years of formal education and MMSE scores between groups. Apolipoprotein E genotyping was performed as previously described ([@b20-grsb-2007-263]). APOE4-positive persons were defined as individuals bearing one or two APOE4 alleles.

Blood samples and extraction
----------------------------

Whole blood was collected and BMC were isolated as previously described ([@b20-grsb-2007-263]). The cell pellet was lysed in Trizol (Invitrogen, Canada) and immediately stored at −80 °C until further processing. Extraction of RNA was performed as described by [@b15-grsb-2007-263] ([@b15-grsb-2007-263]). Briefly, for 1 mL of Trizol, 0.2 mL of chloroform was added and mixed for 15 seconds. After 3 minutes incubation at room temperature (RT), the samples were centrifuged at 12,000 g (4 °C) for 15 min. The upper aqueous layer containing RNA was transferred to another microcentrifuge tube for RNA extraction. Total RNA was solubilized in DEPC-treated water and purified using RNeasy Mini columns (Qiagen, Canada) according to manufacturer instructions.

Small RNA enrichment was performed according to [@b24-grsb-2007-263] ([@b24-grsb-2007-263]). Total RNA samples were adjusted to 400 μL with RNase-free water and then 50 uL of NaCl (5M) and 50 uL PEG 8000 (v/v 50%) were added. The sample was incubated on ice for 2 hours, and centrifuged for 10 minutes at 13 000 rpm (4 °C). Supernatant containing small RNA was transferred to a microcentrifuge tube and 50 uL of sodium acetate (3M, pH 4.6) and 1 mL of 100% ethanol were added. The samples were mixed and incubated at −20 °C for 2 hours and centrifuged for 10 minutes at 12 000 g (4 °C). The supernatant was discarded, and the pellet was washed with 1 mL of cold 75% ethanol and, centrifuged for 10 minutes at 12 000 g (4 °C). The pellet was dried and dissolved in 12 μL of RNase-free water at 60 °C for 10 minutes. Nucleic acid concentrations were determined at 260 nm by spectrophotometry and samples were stored at −80 °C.

MicroRNA profiling
------------------

We applied rigorous selection criteria on samples to control for ethnicity, health status, age and education. Only samples with good yields in total RNA and small RNA enrichment were used ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Small RNA samples were labeled with digoxigenin (DIG) at the 3′ end using the DIG Oligonucleotide Tailing Kit, 2nd Generation (Roche Diagnostics, U.S.A.). One μg of small RNA was labeled in a total volume of 20 μL as described by Wang et al. ([@b34-grsb-2007-263]). The human microRNA microarray (MMChip) consisted of 462 human anti-sense DNA sequences of microRNAs obtained from miRBase (<http://microrna.sanger.ac.uk/>) and spotted on nitrocellulose membrane as described ([@b34-grsb-2007-263]). Microarray chips were pre-hybridized in 1 mL of DIG Easy Hyb solution (Roche Diagnostics, U.S.A.) at 42 °C for 1 hr. DIG-labeled small RNAs from one human subject were added to the membrane and hybridization was performed at 42 °C for 16 hrs. The membrane was washed twice (5 min) in solution 1 (2 × SSC, 0.1% SDS) at RT, incubated for 20 minutes at 37 °C in solution 2 (0.5 × SSC, 0.1% SDS), and 5 minutes in 1× maleic acid solution (100 mM maleic acid, 150 mM NaCl, pH 7.5) at RT. The membrane was blocked in 1.5% Blocking reagent (w/v; Roche Diagnostics, USA). The membrane was incubated for 30 minutes with 1:1500 Anti-Digoxigenin-AP Fab fragments (Roche Diagnostics, U.S.A.). The miRNAs hybridized on the MMchip were revealed by the alkaline phosphatase chromogenic reaction of NBT/BCIP dye as per manufacturer's instructions (Roche Diagnostics, U.S.A.).

Only MMchips with excellent hybridization intensities were analyzed. Hybridization intensities were measured using an Expression 1680 scanner (Epson, U.S.A.) and data acquired using Array-Pro Analyzer 4.5 software (Media Cybernetics, MD, USA). Net intensity was derived from whole cell area measurement and corrected using mean intensity of ring background of surrounding spots. Microarray data analyses were performed with SAM software, version 3.02 (Significance Analysis of Microarrays, Stanford University, CA, U.S.A.). The variable "Block" was used to account for the experimental batches (block effect). Kolmogorov---Smirnov statistics were generated by Gene Set Enrichment Analysis (GSEA) software ([@b33-grsb-2007-263]).

Hierarchical clustering analysis was performed using GenePattern software ([www.broad.mit.edu/cancer/software/genepattern/](www.broad.mit.edu/cancer/software/genepattern/); Broad Institute, MA, U.S.A.) Functional attribution of correlated gene targets was made according to the SOURCE database (<http://source.stanford.edu>) and Gene Ontology Tree Machine (<http://bioinfo.vanderbilt.edu/gotm>).

QRT-PCR validation
------------------

For real time PCR validation, 0.1 μg of small RNA were quantified using the NCode qRT-PCR kit (Invitrogen, U.S.A.). Mature DNA sense sequences of tested miRNAs were used as forward PCR primers. 5S rRNA served as reference gene, and was probed using an internal forward primer (CAGGGTCGGGCCTGGTTAGTACTTG).

For the miRNA let-7f, the qRT-PCR was performed using the TaqMan MicroRNA Reverse Transcription kit, TaqMan MicroArray assay (hsa-let-7f, RT 382) and TaqMan Fast Universal PCR (NoAmpErase UNG;Applied Biosystems, U.S.A.) with 1 ng of small RNA. The TaqMan specific primer U24 small nucleolar RNA (RNU24, RT 1001) was used as reference gene.

All real time PCR reactions were performed on a 7500 Fast System Real Time PCR cycler (Applied Biosystems, U.S.A.) according to manufacturer's instructions. MicroRNA fold changes between diagnostic groups or genders were calculated by the delta Ct method.

Results
=======

MicroRNA expression in Alzheimer BMC
------------------------------------

Mean ages between the NEC (76 ± 6 years) and AD (78 ± 5 years) groups were not significantly different (p = 0.26; [Supplemental Table 1](#SD1){ref-type="supplementary-material"}). Subjects in the AD group had fewer years of formal education (12.6 years as compared to 15 years for NEC, p = 0.05) and scored significantly lower on the MMSE (23/30 as compared to 29/30 for NEC, p \< 0.0001). Yields in small RNA enrichment did not significantly differ between NEC and AD samples (p = 0.95).

The study consisted of 16 NEC and 16 AD miRNA expression profiles, analyzed in four independent experimental blocks with equal numbers of women and men. Only upregulated miRNA expression was found to be significantly altered in Alzheimer BMC by T-statistics ([Table 1](#t1-grsb-2007-263){ref-type="table"}). The relative increases in miRNA in Alzheimer BMC were modest, in the range of 1.1 to 1.4-fold. Significant microarray data analyzed by SAM ([Table 1](#t1-grsb-2007-263){ref-type="table"}) was subsequently ranked by Kolmogorov---Smirnov statistics using the Gene Set Enrichment Analysis (GSEA) software ([@b33-grsb-2007-263]). The enrichments of the significant upregulated miRNA were confirmed for miR-34a and 181b. ([Fig. 1A](#f1-grsb-2007-263){ref-type="fig"}). Although miR-155 was ranked in second position, the fold increase in AD was not validated by quantitative PCR (see below).

We observed slightly different levels of miRNA expression between male and female BMC as illustrated by the heat map generated by GSEA ([Fig. 1A](#f1-grsb-2007-263){ref-type="fig"}), but the differences analyzed by SAM were not significant (data not shown). Next, we stratified NEC and AD miRNA signatures according to APOE4 status ([Table 2](#t2-grsb-2007-263){ref-type="table"}). Similarly to the entire cohort, we found common miRNA upregulated in AD, with tendencies for over-representation of certain miRNA in the APOE4-negative (i.e. miR-34a, 517\*, let-7f, 200a), and possibly the APOE4-positive (i.e. miR-371; miR-181b) strata.

We next performed a higher order analysis of the cohort's miRNA expression signatures by hierarchical clustering using Pearson correlations ([Fig. 1B](#f1-grsb-2007-263){ref-type="fig"}). An apparent classification of NEC and AD was obtained, although three female NEC signatures subgrouped with AD miRNA profiles. The complexity of the different levels of clusters may be related to the inherent experiment block effect existing between the MMchips. Sub-grouping for gender or using the significantly upregulated miRNAs of [Table 1](#t1-grsb-2007-263){ref-type="table"} did not improve the classifications (data not shown).

Real time PCR validation
------------------------

The above comparison for the whole cohort was validated by real time PCR. Levels of selected miRNAs in 10 samples (NEC and AD) were determined by qRT-PCR, and the average Ct values were used to estimate the difference in expression levels between diagnostic groups ([Fig. 2](#f2-grsb-2007-263){ref-type="fig"}).

Of the five selected miRNAs tested by qPCR, only one miRNA (miR-155) was not validated. Importantly, the delta Ct fold differences estimated in AD for miR-34a, 181b, 200a and let-7f corresponded to their order of significance reported in [Table 1](#t1-grsb-2007-263){ref-type="table"}. The qPCR data suggest that the increase in miRNA levels in AD may be underestimated in the microarray platform ([Table 1](#t1-grsb-2007-263){ref-type="table"}).

Target predictions
------------------

Target predictions for the significantly upregulated miRNA in Alzheimer BMC ascertained from the miRBase (Sanger Institute, <http://microrna.sanger.ac.uk/targets/v4/>) were compared with the down-regulated mRNAs previously reported in Alzheimer BMC ([@b20-grsb-2007-263]). Of the predicted hundreds of targets for any specific miRNA, a range of 10 to 30 downregulated transcripts in Alzheimer BMC were correlated, however only transcripts with significantly lower levels in AD are reported in [Table 3](#t3-grsb-2007-263){ref-type="table"}. The percentage of targets per miRNA is reported in [Table 1](#t1-grsb-2007-263){ref-type="table"}. Interestingly, miR-181b, which exhibited the greatest fold-increase expression in Alzheimer BMC, targeted the highest proportion of downregulated genes in AD BMC (31.1%), followed by miR-34a (21.7%). In contrast, targets of miR-200a correlated least with the genomic data (7.5%). Target genes with significantly downregulated transcript levels in AD frequently correlated with miR-181b (NDUFS3, HSF2), let-7f (HERPUD1, TBPL1) and miR-34a (HNRPR, BTF3).

The functional categories for these putative targets are summarized in [Figure 3](#f3-grsb-2007-263){ref-type="fig"}. Interestingly, genes with multifunctional roles in Synapse Activity represented the most extensively targeted category. The enriched GO categories specified by GOTREE for the targeted downregulated genes were: Transcription (P = 0.001), Protein Transport (P = 0.006), and the Peroxisome (P = 0.005). The highest number of individual miRNAs targeting a common gene within the same functional category corresponded to Injury Response/Redox Homeostasis. MicroRNAs let-7f, 34a 181b and 200a shared common targets in several functional categories ([Table 3](#t3-grsb-2007-263){ref-type="table"}).

The enriched GO categories for the downregulated targets identified for some of the individual upregulated miRNAs were as follows: Cell Homeostasis and Peroxisome for miR-34a; Cell Cycle and DNA Damage for miR-181b; and Vesicle Processes for miR-517\*. Represented GO categories were also associated with miRNAs, such as: Cell Cycle with miR-200a and DNA Damage with miR-517\*.

Discussion
==========

Our study was based on the same population described in a previous transcriptome analysis ([@b20-grsb-2007-263]) in order to compare microRNA action and their target genes at the message level. We made a stringent sample selection based on: (1) well-ascertained cases and controls matched for ethnicity, gender and age and (2) excellent total RNA quality and yield of purified microRNA for the screening of 462 currently-known human microRNA species. We found that human BMC expressed a broad range of miRNAs, representing 20% of the 462 miRNA spotted on nitrocellulose membranes in the array format ([Supplemental Table 2](#SD2){ref-type="supplementary-material"}).

MicroRNA expression profiles have shown greater accuracy in classifying cancers than have gene expression profiles ([@b18-grsb-2007-263]). Although our classification of miRNA expression signatures may have been affected by experimental variations, we obtained relatively good discrimination of NEC vs. AD cases. However, the complexity and variability of miRNA expression observed between subjects could have also arisen from the diversity of cell types comprising the BMC fraction ([@b11-grsb-2007-263]). It still remains to be determined whether the miRNA signature of a specific blood mononuclear cell type would be more effective in the classification of neurodegenerative diseases.

Despite the heterogeneity of BMC, we observed a significant increase in the expression of miR-34a and 181b in mild sporadic AD as compared to age-matched normal controls. A higher upregulation of miR-181b in Alzheimer BMC may also occur in APOE4-positive AD subjects. However, the higher FDR of 22% and low number of APOE4-positive chips in the NEC group does not allow us to determine conclusively the impact of APOE4 status on miRNA expression. Nevertheless, the APOE4 allele is associated with an earlier onset of the disease ([@b10-grsb-2007-263]), and higher expression of miRNAs could occur in these subjects as suggested by our results. If validated, induction of miRNA expression may provide a surrogate marker of AD progression.

In this regard, it is interesting to note that a reduction in dicer activity promotes tau toxicity in Drosophila ([@b4-grsb-2007-263]). Thus, certain hallmark neuropathological features of AD may represent events of dysregulated miRNA processing. A reduction of miRNA processivity should instead lead to a decrease in miRNA levels. In fact, increases in miRNAs levels were reported in human AD hippocampus ([@b19-grsb-2007-263]), and this possible paradox in humans should be addressed in future investigations. However, the miRNAs observed in Alzheimer BMC differed from the few miRNAs screened in the latter study. In both studies, induction of specific miRNAs may contribute to the suppression of multiple mRNA species and thereby impact a host of cellular mechanisms ([@b19-grsb-2007-263]). Moreover, concomitant induction of several miRNA species may act in an additive or synergistic manner to inhibit gene expression ([@b14-grsb-2007-263]). In fact, studies have determined that individual microRNAs can downregulate several mRNA species ([@b17-grsb-2007-263]) and induce mRNA instability ([@b31-grsb-2007-263]).

The 3′ UTR of target genes and the cellular context strongly influence the action of miRNA ([@b7-grsb-2007-263]), and our study provides insights leading to the identification of probable miRNA targets in human BMC. We discerned a prevalence of putative downregulated genes in the functional categories of Synapse Activity, Transcription, and Injury/Redox Homeostasis. Importantly, Cell Cycle and DNA Damage related GO categories are targeted by miR-181b, 200a, and 517\*.

Taken together, these observations further support our model linking the development of AD pathology to systemic dysfunction in the cellular stress/antioxidant response and genomic maintenance ([@b20-grsb-2007-263]). These data are commensurate with reports of augmented oxidative DNA and RNA damage and deficient transcription and translation in AD brain and peripheral tissues ([@b21-grsb-2007-263]; [@b30-grsb-2007-263]). The latter impairments may, in turn, contribute to the cytoskeletal abnormalities and neurofibrillary degeneration characteristic of AD-affected neural tissues ([@b20-grsb-2007-263]).

Caution must be exercised in extrapolating from BMC miRNA data sets to gene expression profiles in AD brain given the different 3′ UTR regions inherent to neuronal mRNA relative to peripheral tissues ([@b31-grsb-2007-263]). A wide array of miRNA species should be surveyed in AD-affected brain tissue to determine whether miRNA dysregulation exists therein comparable to that observed in the current Alzheimer BMC study.

The current study provides, to our knowledge, first evidence of augmented microRNA expression in Alzheimer BMC, as well as the framework for future miRNA-target experiments on altered cellular functions related to this disease. For example, miRNAs may account for the suppression of mRNA species implicated in the cellular stress response and DNA repair previously reported in Alzheimer BMC ([@b20-grsb-2007-263]). Dysregulation of BMC miRNA in sporadic AD may shed new light on the pathogenesis of AD and possibly provide useful diagnostic/prognostic biomarkers of this common affliction.

Supplemental Materials
======================

###### 

Demographics of cohort and small RNA yields.

  Diagnosis   Subject ID   Gender   Age   Education   MMSE   APOE   Total RNA (μg)   Small RNA (μg)   Ratio[a](#tfn5-grsb-2007-263){ref-type="table-fn"} (%)
  ----------- ------------ -------- ----- ----------- ------ ------ ---------------- ---------------- --------------------------------------------------------
  NEC         967          F        80    11          29     2,3    41.7             1.2              2.9
  NEC         944          F        68    18          30     3,3    80.4             1.7              2.1
  NEC         1014         F        83    21          29     3,3    73.6             2.1              2.8
  NEC         3R447        F        78    17          29     3,3    23.5             1.1              4.5
  NEC         3R464        F        78    10          28     3,3    115.8            1.2              1.0
  NEC         R787         F        87    15          30     3,3    26.8             1.7              6.5
  NEC         1005         F        68    15          30     3,4    97.0             1.2              1.3
  NEC         1025         F        71    15          28     3,4    51.1             3.4              6.6
  NEC         917          M        72    15          29     3,3    23.5             1.8              7.7
  NEC         923          M        84    12          27     3,3    43.2             1.0              2.2
  NEC         942          M        72    11          29     3,3    57.8             1.9              3.3
  NEC         948          M        80    16          30     3,3    34.9             1.4              4.1
  NEC         R887         M        74    20          30     3,3    56.4             3.1              5.5
  NEC         951          M        80    16          30     3,4    15.1             1.1              7.0
  NEC         R265         M        73    22          30     3,4    44.3             1.0              2.3
  NEC         3R446        M        71    9           29     4,4    62.9             1.7              2.6
  AD          940          F        75    13          21     3,4    52.9             1.1              2.1
  AD          961          F        79    10          23     3,4    100.1            1.8              1.8
  AD          939          F        78    6           27     3,3    76.9             1.1              1.4
  AD          2R411        F        80    14          24     3,3    38.4             2.6              6.8
  AD          1049         F        84    16          24     2,4    18.9             2.6              13.9
  AD          1057         F        72    11          27     3,4    37.6             1.1              2.8
  AD          928          F        81    13          13     2,2    39.4             1.1              2.9
  AD          1033         F        88    12          nd     3,3    48.0             0.9              1.9
  AD          906          M        73    14          25     3,3    28.1             1.3              4.7
  AD          925          M        80    15          28     3,3    52.1             1.4              2.6
  AD          943          M        75    20          17     3,3    77.8             1.6              2.0
  AD          989          M        69    11          21     4,4    36.7             0.9              2.6
  AD          1018         M        76    12          23     4,4    34.3             2.8              8.1
  AD          1022         M        84    12          22     3,4    61.0             2.5              4.1
  AD          2R377        M        81    15          26     3,4    117.0            1.3              1.1
  AD          3R386        M        79    7           25     3,3    73.8             1.8              2.5

Percentage of small RNA over total RNA.

###### 

miRNA expression in elderly human blood mononuclear cells.

  High (intensity 20--8)[a](#tfn6-grsb-2007-263){ref-type="table-fn"}.   Medium (intensity \<7)   Low (intensity \<3)
  ---------------------------------------------------------------------- ------------------------ ---------------------
  hsa-let-7c                                                             hsa-let-7g               hsa-let-7i
  hsa-let-7f                                                             hsa-miR-34a              hsa-miR-10a
  hsa-miR-10b                                                            hsa-miR-34b              hsa-miR-18b
  hsa-miR-18a                                                            hsa-miR-92b              hsa-miR-23b
  hsa-miR-27b                                                            hsa-miR-125b             hsa-miR-26a
  hsa-miR-95                                                             hsa-miR-136              hsa-miR-93
  hsa-miR-137                                                            hsa-miR-181b             hsa-miR-107
  hsa-miR-188                                                            hsa-miR-182              hsa-miR-146a
  hsa-miR-200b                                                           hsa-miR-195              hsa-miR-148a
  hsa-miR-373\*                                                          hsa-miR-200a             hsa-miR-152
  hsa-miR-376a\*                                                         hsa-miR-219              hsa-miR-155
  hsa-miR-377                                                            hsa-miR-373              hsa-miR-192
  hsa-miR-380-5p                                                         hsa-miR-489              hsa-miR-363
  hsa-miR-509                                                            hsa-miR-515-5p           hsa-miR-371
  hsa-miR-510                                                            hsa-miR-518a             hsa-miR-424
  hsa-miR-517\*                                                          hsa-miR-520b             hsa-miR-431
  hsa-miR-520h                                                           hsa-miR-539              hsa-miR-449b
  hsa-miR-523                                                            hsa-miR-548b             hsa-miR-493-3p
  hsa-miR-551a                                                           hsa-miR-562              hsa-miR-513
  hsa-miR-561                                                            hsa-miR-577              hsa-miR-569
  hsa-miR-574                                                            hsa-miR-579              hsa-miR-575
  hsa-miR-582                                                            hsa-miR-600              hsa-miR-581
  hsa-miR-585                                                            hsa-miR-607              hsa-miR-587
  hsa-miR-591                                                            hsa-miR-620              hsa-miR-605
  hsa-miR-598                                                            hsa-miR-623              hsa-miR-608
  hsa-miR-603                                                            hsa-miR-624              hsa-miR-638
  hsa-miR-609                                                            hsa-miR-627              hsa-miR-652
  hsa-miR-612                                                            hsa-miR-646              
  hsa-miR-621                                                            hsa-miR-647              
  hsa-miR-633                                                            hsa-miR-653              
  hsa-miR-641                                                            hsa-miR-661              
  hsa-miR-649                                                                                     
  hsa-miR-659                                                                                     
  hsa-miR-660                                                                                     

Hybridization intensity after DIG immunodetection (see Methods section).
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![Gene set enrichment analysis and hierarchical clustering of microRNA expression in Alzheimer BMC. (**A**) The significantly upregulated miRNA in AD are ranked in order of significance from top to bottom. (**B**) The hierarchical clustering of subjects was determined using Pearson correlation.](grsb-2007-263f1){#f1-grsb-2007-263}

![Quantitative real time PCR of miRNA levels in AD. Fold differences in miRNA levels between NEC and AD were estimated by the delta Ct method.](grsb-2007-263f2){#f2-grsb-2007-263}

![Functional categories of predicted microRNA targets downregulated in Alzheimer BMC. Targets of upregulated BMC miRNA were compared to previous downregulated mRNA data in Alzheimer BMC ([@b20-grsb-2007-263]), and summarized according to percentage of targets per functional category. The average number of miRNAs targeting the same gene within each category is reported.](grsb-2007-263f3){#f3-grsb-2007-263}

###### 

Upregulated microRNA in Alzheimer BMC.

  MicroRNA        Fold change   Score (d)   q-value (%)   BMC targets (%)[a](#tfn2-grsb-2007-263){ref-type="table-fn"}
  --------------- ------------- ----------- ------------- --------------------------------------------------------------
  hsa-miR-34a     1.2           1.3         0.0           21.7
  hsa-miR-579     1.2           1.2         0.0           12.3
  hsa-miR-181b    1.4           1.1         0.0           31.3
  hsa-miR-520h    1.1           1.0         0.0           \-
  hsa-miR-155     1.2           0.9         5.1           \-
  hsa-miR-517\*   1.1           0.9         5.1           11.3
  hsa-let-7f      1.1           0.8         5.1           16.0
  hsa-miR-200a    1.1           0.7         5.1           7.5
  hsa-miR-371     1.1           0.7         5.1           \-

False discovery rate (q-values) was 5.1% of 16 significant miRNAs.

Predicted targets were determined for miRNAs having scores (d) higher than 1.0 or 0% q-values in both Tables 1 and [2](#t2-grsb-2007-263){ref-type="table"}.

###### 

Altered miRNA expression in APOE4-negative and -positive strata

  APOE4 status   MicroRNA        Fold change   Score (d)   q-value (%)
  -------------- --------------- ------------- ----------- -------------
  negative       hsa-miR-34a     1.4           1.8         0.0
  negative       hsa-miR-517\*   1.2           1.7         0.0
  negative       hsa-let-7f      1.2           1.5         0.0
  negative       hsa-miR-200a    1.2           1.4         0.0
  positive       hsa-miR-371     1.4           1.1         22.2
  positive       hsa-miR-181b    1.7           1.0         22.2

False discovery rates (q-values) were 0% in the negative stratum and 22.2% in the positive stratum of 4 and 4 significant miRNAs respectively.

###### 

Predicted miRNA targets downregulated in Alzheimer BMC.

  Upregulated microRNA                Target[a](#tfn4-grsb-2007-263){ref-type="table-fn"}   Target Gene Name                                          Fold change   Score (d)   Function
  ----------------------------------- ----------------------------------------------------- --------------------------------------------------------- ------------- ----------- --------------------------------
  Cell development and metabolism                                                                                                                                               
  181b                                AHCY                                                  S-adenosylhomocysteine hydrolase                          0.46          −1.14       methylation/homocysteine
  34a                                 BCKDK                                                 branched chain alpha- ketoacid dehydrogenase kinase       0.56          −1.91       amino acid pathway
  let-7f; 34a                         FXYD2                                                 FXYD domain containing ion transport regulator 2          0.66          −1.61       ion transport
  34a                                 SHMT1                                                 serine hydroxymethyl- transferase 1                       0.75          −1.59       serine catabolism
  181b                                [GPI]{.ul}                                            glucose phosphate isomerase                               0.75          −1.52       glycolysis
  34a                                 AMPD2                                                 adenosine monophosphate deaminase 2                       0.50          −1.47       energy metabolism (brain)
  181b; 517\*                         HMBS                                                  hydroxymethylbilane synthase                              0.35          −1.24       heme biosynthesis
  34a                                 LTF                                                   lactotransferrin                                          0.15          −0.93       iron homeostasis
  34a                                 CD151                                                 CD151 antigen                                             0.59          −2.66       cell adhesion (sensory neuron)
  181b                                [NDUFS3]{.ul}                                         NADH dehydrogenase Fe-S protein 3                         0.08          −1.19       mitochondrial complex I
                                                                                                                                                                                
  Cell survival program                                                                                                                                                         
  579                                 PSAP                                                  prosaposin                                                0.79          −1.61       anti-apoptotic
  34a                                 BIK                                                   BCL2-interacting killer                                   0.54          −1.01       apoptosis
                                                                                                                                                                                
  CNS and synapse                                                                                                                                                               
  let-7f; 34a                         CRB3                                                  crumbs homolog 3                                          0.39          −2.19       tight junction
  34a                                 P2RY2                                                 purinergic receptor P2Y, G-protein coupled, 2             0.51          −1.84       APP processing
  579                                 RXRG                                                  retinoid X receptor, gamma                                0.49          −1.74       synaptic plasticity
  34a                                 GFAP                                                  glial fibrillary acidic protein                           0.47          −1.65       myelination
  181b; 517\*                         ACTG1                                                 actin, gamma 1                                            0.77          −1.63       axon growth
  34a                                 [HNRPR]{.ul}                                          heterogeneous nuclear ribonucleoprotein R                 0.45          −1.49       axon motor neuron
                                                                                                                                                                                
  DNA repair                                                                                                                                                                    
  181b; 200a                          [MCM3]{.ul}                                           minichromosome maintenance deficient 3                    0.70          −1.68       DNA damage response
  181b                                MMS19L                                                MMS19-like (MET18 homolog)                                0.59          −1.39       DNA repair
                                                                                                                                                                                
  Inflammatory-immune response                                                                                                                                                  
  579                                 [DDT]{.ul}                                            D-dopachrome tautomerase                                  0.76          −2.68       inflammation
  let-7f; 34a                         CHST12                                                carbohydrate sulfotransferase 12                          0.79          −1.85       immune response
  517\*                               LAMP2                                                 lysosomal-associated membrane protein 2                   0.50          −1.73       immune response
  181b                                SLA                                                   Src-like-adaptor                                          0.53          −1.41       immune response
                                                                                                                                                                                
  Injury response-redox homeostasis                                                                                                                                             
  let-7f; 200a                        HERPUD1                                               homocysteine-inducible, ubiquitin-likedomainmember1       0.41          −2.26       stress response
  517\*                               HMGN2                                                 high-mobility group nucleosomal binding domain 2          0.71          −1.71       oxidative stress
  let-7f; 181b                        [TBPL1]{.ul}                                          TBP-like 1                                                0.41          −1.69       stress response
  181b                                [HSF2]{.ul}                                           heat shock transcription factor 2                         0.34          −1.64       stress response
                                                                                                                                                                                
  Lipid metabolism                                                                                                                                                              
  let-7f                              ELA3B                                                 elastase 3B, pancreatic                                   0.53          −2.87       cholesterol biosynthesis
  181b                                FDXR                                                  ferredoxin reductase                                      0.51          −1.85       cholesterol biosynthesis
  let-7f; 34a                         MECR                                                  mitochondrial trans-2- enoyl-CoA reductase                0.50          −1.17       fatty acid metabolism
                                                                                                                                                                                
  Proteasome-lysosome-transport                                                                                                                                                 
  579                                 [UBE2M]{.ul}                                          ubiquitin-conjugating enzyme E2M                          0.50          −2.13       ubiquitin cycle
  181b                                [DNAJC7]{.ul}                                         DnaJ (Hsp40) homolog, subfamily C, member 7               0.76          −1.82       protein folding
  181b                                NDRG2                                                 NDRG family member 2                                      0.43          −1.76       protein chaperone (misfolded)
  579                                 SNX2                                                  sorting nexin 2                                           0.34          −1.68       protein sorting
                                                                                                                                                                                
  Signal transduction                                                                                                                                                           
  181b                                AGGF1                                                 Angiogenic factor with G patch and FHA domains 1          0.54          −1.44       signal transduction
  181b                                MAP3K6                                                mitogen-activated protein kinase kinase kinase 6          0.58          −0.93       signal transduction
                                                                                                                                                                                
  Transcripion-translation                                                                                                                                                      
  34a                                 BTF3                                                  basic transcription factor 3                              0.45          −3.31       transcription
  200a                                [DDX5]{.ul}                                           DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 5            0.73          −2.34       spliceosome
  34a                                 [IRF1]{.ul}                                           interferon regulatory factor 1                            0.59          −1.46       transcription
  let-7f; 181b                        TAF1A                                                 TATA box binding protein- assoc. factor, RNApol I, A      0.58          −1.35       transcription (rRNA)
                                                                                                                                                                                
  Unknown                                                                                                                                                                       
  517\*                               [MLF2]{.ul}                                           myeloid leukemia factor 2                                 0.71          −2.04       unknown
  181b; 579                           [BEX2]{.ul}                                           Brain expressed X-linked 2                                0.33          −1.89       unknown (brain)
  let7f; 181b; 579                    SSX2                                                  synovial sarcoma, X breakpoint 2                          0.46          −1.75       unknown
  517\*                               ZNF691                                                zinc finger protein 691                                   0.14          −1.60       unknown
  181b                                RBMXL1                                                RNA binding motif protein, X-linked-like 1                0.42          −1.27       unknown
  let-7f, 517\*                       OBFC1                                                 oligonucleotide/oligosaccharide- bindingfoldcontaining1   0.55          −1.11       unknown

Underlined gene symbols indicate similar down-regulation in AD affected brains ([@b20-grsb-2007-263]).
